An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer

BACKGROUND: Combining anti-cancer therapies with orthogonal modes of action, such as direct cytotoxicity and immunostimulatory, hold promise for expanding clinical benefit to patients with metastatic disease. For instance, a chemotherapy agent Oxaliplatin (OXP) in combination with Interleukin-12 (IL...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qing, Wang, Zhijun, Wu, Yan, Klinke, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950805/
https://www.ncbi.nlm.nih.gov/pubmed/31914948
http://dx.doi.org/10.1186/s12885-019-6500-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950805/
https://www.ncbi.nlm.nih.gov/pubmed/31914948
http://dx.doi.org/10.1186/s12885-019-6500-9

Ejemplares similares